Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology

The present multicenter retrospective study on eltrombopag administration in Italian children with chronic ITP aims to extend follow-up of our previous study. This retrospective multicenter study was conducted in 17 centers affiliated to the Italian Association of Pediatric Hematology and Oncology (...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in medicine 2023-07, Vol.10, p.1214308-1214308
Main Authors: Giordano, Paola, Lassandro, Giuseppe, Barone, Angelica, Cesaro, Simone, Fotzi, Ilaria, Giona, Fiorina, Gorio, Chiara, Maggio, Angela, Miano, Maurizio, Marzollo, Antonio, Nardi, Margherita, Pession, Andrea, Ruggiero, Antonio, Russo, Giovanna, Saracco, Paola, Spinelli, Marco, Tolva, Alessandra, Tornesello, Assunta, Palladino, Valentina, Del Vecchio, Giovanni Carlo
Format: Article
Language:English
Subjects:
bleeding disorders
children
eltrombopag
immune thrombocytopenia
Medicine
thrombopoietin receptor agonists
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c418t-cf96867ff060b588f04f4417df1fdb66feb6efbf263209a4ca780b009aa0bdfe3
container_end_page 1214308
container_issue
container_start_page 1214308
container_title Frontiers in medicine
container_volume 10
creator Giordano, Paola
Lassandro, Giuseppe
Barone, Angelica
Cesaro, Simone
Fotzi, Ilaria
Giona, Fiorina
Gorio, Chiara
Maggio, Angela
Miano, Maurizio
Marzollo, Antonio
Nardi, Margherita
Pession, Andrea
Ruggiero, Antonio
Russo, Giovanna
Saracco, Paola
Spinelli, Marco
Tolva, Alessandra
Tornesello, Assunta
Palladino, Valentina
Del Vecchio, Giovanni Carlo
description The present multicenter retrospective study on eltrombopag administration in Italian children with chronic ITP aims to extend follow-up of our previous study. This retrospective multicenter study was conducted in 17 centers affiliated to the Italian Association of Pediatric Hematology and Oncology (AIEOP). Patients were classified into three subgroups: group 1 included patients who discontinued treatment due to a stable platelet count; group 2 included patients who discontinued treatment due to ineffectiveness; group 3 included patients who did not permanently discontinue treatment. 56 patients were eligible for analysis. The median duration of eltrombopag treatment was 40 months (7-71 months). Twenty patients (36%) discontinued permanently eltrombopag. The reasons of permanent discontinuation were adverse effects ( = 1), inefficacy ( = 10), stable platelet count ( = 9). All patients of group 1 maintained a durable response without additional treatments after eltrombopag discontinuation. We found that patients of group 2 were on treatment for less time (median treatment time: 13.5 months, min: 6.0 - max: 56.0) than patients of group 1 (median treatment time: 34 months, min: 16.0 - max: 62.0) (
doi_str_mv 10.3389/fmed.2023.1214308
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_12dd79de099940298390b720c4a7ae60</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_12dd79de099940298390b720c4a7ae60</doaj_id><sourcerecordid>2844094447</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-cf96867ff060b588f04f4417df1fdb66feb6efbf263209a4ca780b009aa0bdfe3</originalsourceid><addsrcrecordid>eNpVUstuEzEUHSEQrUo_gA3ykk2CX5nxsEFVBTRSpLIAiZ3lsa8TVx578HgK-cF-Vz1JqNqV7-Pcc2zfU1XvCV4yJtpPtgezpJiyJaGEMyxeVeeUtvVCrMTv18_is-pyHO8wxoTRFSfsbXXGmhUljNPz6mETwxZlSD2aRkDRIvA5xb6Lg9oiF5DeOW8SBPTX5V3JUgxOI9f3UwCUdweo3uc4QHDqM4J_GYIBgxIoj7yzUKJCOA6gs7sH1E8-Ow2hSBbwAMlB0AfhvAO0zso7FdDVOEbtVHYxzK0fYEqSivAN9CpHH7d7pIJBt0EfknfVG6v8CJen86L69e3rz-ubxeb2-_r6arPQnIi80LatRd1Yi2vcrYSwmFvOSWMssaarawtdDbaztGYUt4pr1Qjc4RIq3BkL7KJaH3lNVHdySK5XaS-jcvJQiGkrVSrv8yAJNaZpDeC2bTmmrWAt7hqKNVeNghoXri9HrmHqyi7nP0nKvyB92QluJ7fxXhI870-IwvDxxJDinwnGLHs3avBeBYjTKKngHLec86ZAyRGqyy7GBPZJh2A5-0nOfpKzn-TJT2Xmw_MLPk38dw97BOvyzgs</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2844094447</pqid></control><display><type>article</type><title>Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology</title><source>PubMed Central Free</source><creator>Giordano, Paola ; Lassandro, Giuseppe ; Barone, Angelica ; Cesaro, Simone ; Fotzi, Ilaria ; Giona, Fiorina ; Gorio, Chiara ; Maggio, Angela ; Miano, Maurizio ; Marzollo, Antonio ; Nardi, Margherita ; Pession, Andrea ; Ruggiero, Antonio ; Russo, Giovanna ; Saracco, Paola ; Spinelli, Marco ; Tolva, Alessandra ; Tornesello, Assunta ; Palladino, Valentina ; Del Vecchio, Giovanni Carlo</creator><creatorcontrib>Giordano, Paola ; Lassandro, Giuseppe ; Barone, Angelica ; Cesaro, Simone ; Fotzi, Ilaria ; Giona, Fiorina ; Gorio, Chiara ; Maggio, Angela ; Miano, Maurizio ; Marzollo, Antonio ; Nardi, Margherita ; Pession, Andrea ; Ruggiero, Antonio ; Russo, Giovanna ; Saracco, Paola ; Spinelli, Marco ; Tolva, Alessandra ; Tornesello, Assunta ; Palladino, Valentina ; Del Vecchio, Giovanni Carlo</creatorcontrib><description>The present multicenter retrospective study on eltrombopag administration in Italian children with chronic ITP aims to extend follow-up of our previous study. This retrospective multicenter study was conducted in 17 centers affiliated to the Italian Association of Pediatric Hematology and Oncology (AIEOP). Patients were classified into three subgroups: group 1 included patients who discontinued treatment due to a stable platelet count; group 2 included patients who discontinued treatment due to ineffectiveness; group 3 included patients who did not permanently discontinue treatment. 56 patients were eligible for analysis. The median duration of eltrombopag treatment was 40 months (7-71 months). Twenty patients (36%) discontinued permanently eltrombopag. The reasons of permanent discontinuation were adverse effects ( = 1), inefficacy ( = 10), stable platelet count ( = 9). All patients of group 1 maintained a durable response without additional treatments after eltrombopag discontinuation. We found that patients of group 2 were on treatment for less time (median treatment time: 13.5 months, min: 6.0 - max: 56.0) than patients of group 1 (median treatment time: 34 months, min: 16.0 - max: 62.0) ( &lt; 0.05). Patients of group 2 mostly did not achieve a stable platelet count in the first 6 months of treatment and underwent concomitant therapies during follow-up respect of group 1 and group 3 ( &lt; 0.01). Our study found that the benefits of eltrombopag treatment, in terms of platelet count improvement and use of additional therapies, are identifiable from the first 6 months of treatment.</description><identifier>ISSN: 2296-858X</identifier><identifier>EISSN: 2296-858X</identifier><identifier>DOI: 10.3389/fmed.2023.1214308</identifier><identifier>PMID: 37521342</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>bleeding disorders ; children ; eltrombopag ; immune thrombocytopenia ; Medicine ; thrombopoietin receptor agonists</subject><ispartof>Frontiers in medicine, 2023-07, Vol.10, p.1214308-1214308</ispartof><rights>Copyright © 2023 Giordano, Lassandro, Barone, Cesaro, Fotzi, Giona, Gorio, Maggio, Miano, Marzollo, Nardi, Pession, Ruggiero, Russo, Saracco, Spinelli, Tolva, Tornesello, Palladino and Del Vecchio.</rights><rights>Copyright © 2023 Giordano, Lassandro, Barone, Cesaro, Fotzi, Giona, Gorio, Maggio, Miano, Marzollo, Nardi, Pession, Ruggiero, Russo, Saracco, Spinelli, Tolva, Tornesello, Palladino and Del Vecchio. 2023 Giordano, Lassandro, Barone, Cesaro, Fotzi, Giona, Gorio, Maggio, Miano, Marzollo, Nardi, Pession, Ruggiero, Russo, Saracco, Spinelli, Tolva, Tornesello, Palladino and Del Vecchio</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c418t-cf96867ff060b588f04f4417df1fdb66feb6efbf263209a4ca780b009aa0bdfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375288/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375288/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37521342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giordano, Paola</creatorcontrib><creatorcontrib>Lassandro, Giuseppe</creatorcontrib><creatorcontrib>Barone, Angelica</creatorcontrib><creatorcontrib>Cesaro, Simone</creatorcontrib><creatorcontrib>Fotzi, Ilaria</creatorcontrib><creatorcontrib>Giona, Fiorina</creatorcontrib><creatorcontrib>Gorio, Chiara</creatorcontrib><creatorcontrib>Maggio, Angela</creatorcontrib><creatorcontrib>Miano, Maurizio</creatorcontrib><creatorcontrib>Marzollo, Antonio</creatorcontrib><creatorcontrib>Nardi, Margherita</creatorcontrib><creatorcontrib>Pession, Andrea</creatorcontrib><creatorcontrib>Ruggiero, Antonio</creatorcontrib><creatorcontrib>Russo, Giovanna</creatorcontrib><creatorcontrib>Saracco, Paola</creatorcontrib><creatorcontrib>Spinelli, Marco</creatorcontrib><creatorcontrib>Tolva, Alessandra</creatorcontrib><creatorcontrib>Tornesello, Assunta</creatorcontrib><creatorcontrib>Palladino, Valentina</creatorcontrib><creatorcontrib>Del Vecchio, Giovanni Carlo</creatorcontrib><title>Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology</title><title>Frontiers in medicine</title><addtitle>Front Med (Lausanne)</addtitle><description>The present multicenter retrospective study on eltrombopag administration in Italian children with chronic ITP aims to extend follow-up of our previous study. This retrospective multicenter study was conducted in 17 centers affiliated to the Italian Association of Pediatric Hematology and Oncology (AIEOP). Patients were classified into three subgroups: group 1 included patients who discontinued treatment due to a stable platelet count; group 2 included patients who discontinued treatment due to ineffectiveness; group 3 included patients who did not permanently discontinue treatment. 56 patients were eligible for analysis. The median duration of eltrombopag treatment was 40 months (7-71 months). Twenty patients (36%) discontinued permanently eltrombopag. The reasons of permanent discontinuation were adverse effects ( = 1), inefficacy ( = 10), stable platelet count ( = 9). All patients of group 1 maintained a durable response without additional treatments after eltrombopag discontinuation. We found that patients of group 2 were on treatment for less time (median treatment time: 13.5 months, min: 6.0 - max: 56.0) than patients of group 1 (median treatment time: 34 months, min: 16.0 - max: 62.0) ( &lt; 0.05). Patients of group 2 mostly did not achieve a stable platelet count in the first 6 months of treatment and underwent concomitant therapies during follow-up respect of group 1 and group 3 ( &lt; 0.01). Our study found that the benefits of eltrombopag treatment, in terms of platelet count improvement and use of additional therapies, are identifiable from the first 6 months of treatment.</description><subject>bleeding disorders</subject><subject>children</subject><subject>eltrombopag</subject><subject>immune thrombocytopenia</subject><subject>Medicine</subject><subject>thrombopoietin receptor agonists</subject><issn>2296-858X</issn><issn>2296-858X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUstuEzEUHSEQrUo_gA3ykk2CX5nxsEFVBTRSpLIAiZ3lsa8TVx578HgK-cF-Vz1JqNqV7-Pcc2zfU1XvCV4yJtpPtgezpJiyJaGEMyxeVeeUtvVCrMTv18_is-pyHO8wxoTRFSfsbXXGmhUljNPz6mETwxZlSD2aRkDRIvA5xb6Lg9oiF5DeOW8SBPTX5V3JUgxOI9f3UwCUdweo3uc4QHDqM4J_GYIBgxIoj7yzUKJCOA6gs7sH1E8-Ow2hSBbwAMlB0AfhvAO0zso7FdDVOEbtVHYxzK0fYEqSivAN9CpHH7d7pIJBt0EfknfVG6v8CJen86L69e3rz-ubxeb2-_r6arPQnIi80LatRd1Yi2vcrYSwmFvOSWMssaarawtdDbaztGYUt4pr1Qjc4RIq3BkL7KJaH3lNVHdySK5XaS-jcvJQiGkrVSrv8yAJNaZpDeC2bTmmrWAt7hqKNVeNghoXri9HrmHqyi7nP0nKvyB92QluJ7fxXhI870-IwvDxxJDinwnGLHs3avBeBYjTKKngHLec86ZAyRGqyy7GBPZJh2A5-0nOfpKzn-TJT2Xmw_MLPk38dw97BOvyzgs</recordid><startdate>20230714</startdate><enddate>20230714</enddate><creator>Giordano, Paola</creator><creator>Lassandro, Giuseppe</creator><creator>Barone, Angelica</creator><creator>Cesaro, Simone</creator><creator>Fotzi, Ilaria</creator><creator>Giona, Fiorina</creator><creator>Gorio, Chiara</creator><creator>Maggio, Angela</creator><creator>Miano, Maurizio</creator><creator>Marzollo, Antonio</creator><creator>Nardi, Margherita</creator><creator>Pession, Andrea</creator><creator>Ruggiero, Antonio</creator><creator>Russo, Giovanna</creator><creator>Saracco, Paola</creator><creator>Spinelli, Marco</creator><creator>Tolva, Alessandra</creator><creator>Tornesello, Assunta</creator><creator>Palladino, Valentina</creator><creator>Del Vecchio, Giovanni Carlo</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230714</creationdate><title>Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology</title><author>Giordano, Paola ; Lassandro, Giuseppe ; Barone, Angelica ; Cesaro, Simone ; Fotzi, Ilaria ; Giona, Fiorina ; Gorio, Chiara ; Maggio, Angela ; Miano, Maurizio ; Marzollo, Antonio ; Nardi, Margherita ; Pession, Andrea ; Ruggiero, Antonio ; Russo, Giovanna ; Saracco, Paola ; Spinelli, Marco ; Tolva, Alessandra ; Tornesello, Assunta ; Palladino, Valentina ; Del Vecchio, Giovanni Carlo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-cf96867ff060b588f04f4417df1fdb66feb6efbf263209a4ca780b009aa0bdfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>bleeding disorders</topic><topic>children</topic><topic>eltrombopag</topic><topic>immune thrombocytopenia</topic><topic>Medicine</topic><topic>thrombopoietin receptor agonists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giordano, Paola</creatorcontrib><creatorcontrib>Lassandro, Giuseppe</creatorcontrib><creatorcontrib>Barone, Angelica</creatorcontrib><creatorcontrib>Cesaro, Simone</creatorcontrib><creatorcontrib>Fotzi, Ilaria</creatorcontrib><creatorcontrib>Giona, Fiorina</creatorcontrib><creatorcontrib>Gorio, Chiara</creatorcontrib><creatorcontrib>Maggio, Angela</creatorcontrib><creatorcontrib>Miano, Maurizio</creatorcontrib><creatorcontrib>Marzollo, Antonio</creatorcontrib><creatorcontrib>Nardi, Margherita</creatorcontrib><creatorcontrib>Pession, Andrea</creatorcontrib><creatorcontrib>Ruggiero, Antonio</creatorcontrib><creatorcontrib>Russo, Giovanna</creatorcontrib><creatorcontrib>Saracco, Paola</creatorcontrib><creatorcontrib>Spinelli, Marco</creatorcontrib><creatorcontrib>Tolva, Alessandra</creatorcontrib><creatorcontrib>Tornesello, Assunta</creatorcontrib><creatorcontrib>Palladino, Valentina</creatorcontrib><creatorcontrib>Del Vecchio, Giovanni Carlo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giordano, Paola</au><au>Lassandro, Giuseppe</au><au>Barone, Angelica</au><au>Cesaro, Simone</au><au>Fotzi, Ilaria</au><au>Giona, Fiorina</au><au>Gorio, Chiara</au><au>Maggio, Angela</au><au>Miano, Maurizio</au><au>Marzollo, Antonio</au><au>Nardi, Margherita</au><au>Pession, Andrea</au><au>Ruggiero, Antonio</au><au>Russo, Giovanna</au><au>Saracco, Paola</au><au>Spinelli, Marco</au><au>Tolva, Alessandra</au><au>Tornesello, Assunta</au><au>Palladino, Valentina</au><au>Del Vecchio, Giovanni Carlo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology</atitle><jtitle>Frontiers in medicine</jtitle><addtitle>Front Med (Lausanne)</addtitle><date>2023-07-14</date><risdate>2023</risdate><volume>10</volume><spage>1214308</spage><epage>1214308</epage><pages>1214308-1214308</pages><issn>2296-858X</issn><eissn>2296-858X</eissn><abstract>The present multicenter retrospective study on eltrombopag administration in Italian children with chronic ITP aims to extend follow-up of our previous study. This retrospective multicenter study was conducted in 17 centers affiliated to the Italian Association of Pediatric Hematology and Oncology (AIEOP). Patients were classified into three subgroups: group 1 included patients who discontinued treatment due to a stable platelet count; group 2 included patients who discontinued treatment due to ineffectiveness; group 3 included patients who did not permanently discontinue treatment. 56 patients were eligible for analysis. The median duration of eltrombopag treatment was 40 months (7-71 months). Twenty patients (36%) discontinued permanently eltrombopag. The reasons of permanent discontinuation were adverse effects ( = 1), inefficacy ( = 10), stable platelet count ( = 9). All patients of group 1 maintained a durable response without additional treatments after eltrombopag discontinuation. We found that patients of group 2 were on treatment for less time (median treatment time: 13.5 months, min: 6.0 - max: 56.0) than patients of group 1 (median treatment time: 34 months, min: 16.0 - max: 62.0) ( &lt; 0.05). Patients of group 2 mostly did not achieve a stable platelet count in the first 6 months of treatment and underwent concomitant therapies during follow-up respect of group 1 and group 3 ( &lt; 0.01). Our study found that the benefits of eltrombopag treatment, in terms of platelet count improvement and use of additional therapies, are identifiable from the first 6 months of treatment.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>37521342</pmid><doi>10.3389/fmed.2023.1214308</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-858X
ispartof Frontiers in medicine, 2023-07, Vol.10, p.1214308-1214308
issn 2296-858X
2296-858X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_12dd79de099940298390b720c4a7ae60
source PubMed Central Free
subjects bleeding disorders
children
eltrombopag
immune thrombocytopenia
Medicine
thrombopoietin receptor agonists
title Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A21%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20term%20use%20of%20eltrombopag%20in%20children%20with%20chronic%20immune%20thrombocytopenia:%20extended%20real%20life%20retrospective%20multicenter%20experience%20of%20the%20Italian%20Association%20of%20Pediatric%20Hematology%20and%20Oncology&rft.jtitle=Frontiers%20in%20medicine&rft.au=Giordano,%20Paola&rft.date=2023-07-14&rft.volume=10&rft.spage=1214308&rft.epage=1214308&rft.pages=1214308-1214308&rft.issn=2296-858X&rft.eissn=2296-858X&rft_id=info:doi/10.3389/fmed.2023.1214308&rft_dat=%3Cproquest_doaj_%3E2844094447%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-cf96867ff060b588f04f4417df1fdb66feb6efbf263209a4ca780b009aa0bdfe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2844094447&rft_id=info:pmid/37521342&rfr_iscdi=true